Lantheus Holdings, Inc. (LNTH)

NASDAQ: LNTH · IEX Real-Time Price · USD
79.67
-1.43 (-1.76%)
At close: May 17, 2024, 4:00 PM
79.99
+0.32 (0.40%)
After-hours: May 17, 2024, 6:50 PM EDT
-1.76%
Market Cap 5.52B
Revenue (ttm) 1.37B
Net Income (ttm) 460.53M
Shares Out 69.31M
EPS (ttm) 6.55
PE Ratio 12.16
Forward PE 11.23
Dividend n/a
Ex-Dividend Date n/a
Volume 732,080
Open 81.34
Previous Close 81.10
Day's Range 79.59 - 82.10
52-Week Range 50.20 - 100.48
Beta 0.52
Analysts Strong Buy
Price Target 99.17 (+24.48%)
Earnings Date May 2, 2024

About LNTH

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or r... [Read more]

Sector Healthcare
IPO Date Jun 25, 2015
Employees 834
Stock Exchange NASDAQ
Ticker Symbol LNTH
Full Company Profile

Financial Performance

In 2023, LNTH's revenue was $1.30 billion, an increase of 38.65% compared to the previous year's $935.06 million. Earnings were $326.66 million, an increase of 1063.86%.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for LNTH stock is "Strong Buy." The 12-month stock price forecast is $99.17, which is an increase of 24.48% from the latest price.

Price Target
$99.17
(24.48% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Lantheus Announces Executive Appointments to Accelerate Innovation

Jeffrey S. Humphrey, MD appointed Chief Medical Officer; Jean-Claude Provost, MD named Chief Science Officer

3 days ago - GlobeNewsWire

Lantheus Reports First Quarter 2024 Financial Results

First Quarter 2024 Worldwide revenue of $370.0 million, an increase of 23.0% from first quarter 2023  GAAP fully diluted net income per share of $1.87, compared to GAAP fully diluted net loss per shar...

16 days ago - GlobeNewsWire

Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time

BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, M...

4 weeks ago - GlobeNewsWire

Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024

BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight ...

2 months ago - GlobeNewsWire

Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer

BEDFORD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight a...

2 months ago - GlobeNewsWire

Lantheus to Present at the TD Cowen 44th Annual Health Care Conference

BEDFORD, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight a...

2 months ago - GlobeNewsWire

Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results

BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) --  Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...

3 months ago - GlobeNewsWire

Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging

Lantheus to supply MK-6240, an investigational F18-labeled PET imaging agent that targets tau tangles BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LN...

3 months ago - GlobeNewsWire

Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time

BEDFORD, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, Fe...

3 months ago - GlobeNewsWire

Lantheus Announces CEO Succession Plan

Lantheus Board Member and Pharmaceutical Industry Veteran Brian Markison Appointed Lantheus Chief Executive Officer, Effective March 1, 2024

4 months ago - GlobeNewsWire

Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)

BEDFORD, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians...

4 months ago - GlobeNewsWire

Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics

Option to license Perspective Therapeutics' Pb212-VMT-α-NET asset Co-development rights for certain Pb212-based alpha therapies for prostate cancer Equity investment of up to 19.9% in Perspective Ther...

4 months ago - GlobeNewsWire

Lantheus Reports Preliminary Fiscal Year 2023 Revenue

Full year 2023 worldwide revenue expected to be in the range of $1.295 – 1.297 billion, a 38 - 39% increase over the prior year including a $15 million RELISTOR milestone achievement

4 months ago - GlobeNewsWire

Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight a...

4 months ago - GlobeNewsWire

20 midcap stocks with 2024 upside ranging up to 62%, according to analysts

When investors think about whether to increase their exposure beyond the big companies that grab most of the headlines in the financial media, they are likely to look at small-cap stocks first. After ...

5 months ago - Market Watch

Lantheus and Point Biopharma shares drop on prostate cancer treatment data

Shares of Lantheus Holdings Inc. LNTH, -2.38% and Point Biopharma Global Inc. PNT, +2.26% fell sharply premarket on Monday after the companies released new data from a trial of their experimental trea...

5 months ago - Market Watch

Lantheus to Present at the Jefferies London Healthcare Conference

BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight a...

6 months ago - GlobeNewsWire

Lantheus Reports Third Quarter 2023 Financial Results

BEDFORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight ...

7 months ago - GlobeNewsWire

Lantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on November 2, 2023, at 8:00 a.m. Eastern Time

BEDFORD, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) --  Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, N...

7 months ago - GlobeNewsWire

Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting

BEDFORD, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and ar...

9 months ago - GlobeNewsWire

Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty

Agreement enhances Lantheus' strong liquidity position and supports continued pipeline advancement and commercial readiness Agreement enhances Lantheus' strong liquidity position and supports continue...

10 months ago - GlobeNewsWire

Lantheus Reports Second Quarter 2023 Financial Results

BEDFORD, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and art...

10 months ago - GlobeNewsWire

Lantheus to Host Second Quarter 2023 Earnings Conference Call and Webcast on August 3, 2023, at 8:00 a.m. Eastern Time

BEDFORD, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, Au...

10 months ago - GlobeNewsWire

Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

BEDFORD, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and art...

1 year ago - GlobeNewsWire

Lantheus to Present at the Jefferies Healthcare Conference

BEDFORD, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and arti...

1 year ago - GlobeNewsWire